BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Fc fusion to Glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation

  • Published : 2009.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The short in vivo half-life of GLP-1 prevents it from being used clinically. This short half-life occurs because GLP-1 is rapidly degraded by dipeptidyl peptidases such as DPP-IV. To overcome this obstacle, a GLP-1/Fc was constructed and evaluated to determine if it was degraded by DPP-IV and in serum. When the degradation of GLP-1/Fc by human DPP-IV and rabbit serum was compared with that of GLP-1 it was found to be reduced by approximately 5- and 4-fold, respectively. Furthermore, GLP-1/Fc showed a potent activity for human GLP-1 receptor activation ($EC_{50}$ approximately 6 nM). Taken together, these results indicate that GLP-1/Fc may have an extended half-life in vivo that occurs as a result of inhibition of degradation by human DPP-IV. Due to the extended half life, GLP-1/Fc may be useful for clinical treatments.

Keywords

References

  1. Moens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E. and Ling, Z. (1996) Expression and functional activity of glucagon, glucagon-like activity peptide 1, and glucose-dependent insulinotrophic peptide receptors in rat pancreatic islet cells. Diabetes 45, 257-261 https://doi.org/10.2337/diabetes.45.2.257
  2. Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Goke, B. and Thorens, B. (2003) The glucagons receptor family. Pharmacol. Rev. 55, 167-194 https://doi.org/10.1124/pr.55.1.6
  3. Trumper, A., Trumper, K., Trusheim, A., Arnold, R., Goke, B. and Horsch, D. (2001) Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 15, 1559-1570 https://doi.org/10.1210/me.15.9.1559
  4. Wrede, C. E., Dickson, L. M., Lingohr, M. K., Briaud, I. and Rhodes, C. J. (2002) Protein kinase B/Akt prevent fatty acid-induced apoptosis in pancreatic beta-cells (INS-1). J. Biol. Chem. 277, 49676-49684 https://doi.org/10.1074/jbc.M208756200
  5. Wang, Q., Li, L., Xu, E., Wong, V., Rhodes, C. and Brubaker, P. L. (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS beta-cells. Diabetologia 47, 478-487 https://doi.org/10.1007/s00125-004-1327-5
  6. Drucker, D. J. (2003) Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144, 5145-5148 https://doi.org/10.1210/en.2003-1147
  7. Li, L., El-Kholy, W., Rhodes, C. J. and Brubaker, P. L. (2005) Glucagon-like peptide-1 protects beta cells from cytokinesinduced apoptosis and necrosis: role of protein kinase. Diabetologia 48, 1339-1349 https://doi.org/10.1007/s00125-005-1787-2
  8. Gao, H., Wang, X., Zhang, Z., Yang, Y., Yang, J., Li, X. and Ning, G. (2007) GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine 32, 90-95 https://doi.org/10.1007/s12020-007-9011-4
  9. Nguyen, L. L., Kriketos, A. D., Hancock, D. P., Caterson, I. D. and Denyer, G. S. (2006) Insulin resistance does not influence gene expression in skeletal muscle. BMB Reports 39, 457-463
  10. Drucker, D. J. (2002) Biological actions and therapeutic potential of the glucagons-like peptides. Gastroenterology 291, 1302-1308
  11. Drucker, D. J. (2001) Mini-review: the glucagons-like peptides. Endocrinology 142, 521-527 https://doi.org/10.1210/en.142.2.521
  12. Wang, Q. and Brubaker, P. L. (2002) Glucagon-like peptide- 1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45, 1263-1273 https://doi.org/10.1007/s00125-002-0828-3
  13. Drucker, D. J. and Nauck, M. A. (2006) The incretin system: glucagon-like prptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1969-1705
  14. Kumar, M., Hunag, Y., Glinka, Y., Prud'homme, G. J. and Wanh, Q. (2007) In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin- induced diabetes. Gene Therapy 14, 162-172
  15. Farilla, L., Bulotta, A., Hirshberg, B., Li, B., Calzi, S., Khoury, N. and Noushmehr, H. (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144, 5149-5158 https://doi.org/10.1210/en.2003-0323
  16. Mentlien, R. (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 85, 9-24 https://doi.org/10.1016/S0167-0115(99)00089-0
  17. Deacon, C. F., Johnsen, A. H. and Holst, J. J. (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 82, 952-957
  18. Lee, D. H., Chun, C., Kim, S. H. and Lee, C. Y. (2005) Expression of Porcine Acid-labile Subunit (pALS) of the 150-kilodalton Ternary Insulin-like Growth Factor Complex and Initial Characterization of Recombinant pALS Protein, BMB Reports 38, 225-231

Cited by

  1. Early Engineering Approaches to Improve Peptide Developability and Manufacturability vol.17, pp.1, 2015, https://doi.org/10.1208/s12248-014-9681-9
  2. Targeting the glucagon receptor family for diabetes and obesity therapy vol.135, pp.3, 2012, https://doi.org/10.1016/j.pharmthera.2012.05.009
  3. Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo vol.229, 2016, https://doi.org/10.1016/j.jconrel.2016.03.017
  4. TNF receptor II fusion protein with tandemly repeated Fc domains vol.149, pp.3, 2011, https://doi.org/10.1093/jb/mvq149